**Relationship between High Resolution CT Chest and Laboratory Parameters- An Assessment Tool for the Safe and Timely Management of Suspected/Confirmed Covid-19 Disease Patients**

Sanum Kashif¹, Erum Pervaiz²

**Objective:** To assess the relationship between radiological findings and laboratory parameters, for safe and timely management of COVID-19 disease patients.

**Study Design:** Retrospective observational study.

**Place and Duration of Study:** The study was conducted at COVID-19 isolation ward of Frontier Corps Hospital Quetta, from April 15th to June 30th, 2020.

**Materials and Methods:** Suspected COVID-19 (on the basis of history) patients, from April 15th to June 30th, 2020, were included in the study. Laboratory parameters including, Neutrophils, Lymphocytes, C-Reactive Protein (CRP) were retrospectively collected from medical records. Severity of lung changes on high resolution chest CT was scored according to the lung involvement (CO-RADS score 1-6). Spearman rank correlation was used to evaluate the relationship between CO-RADS score and laboratory parameters.

**Results:** A total of 50 patients (mean age 34.7±6.46 years [standard deviation]; age range, 23-49 years) were evaluated. The patients underwent a total of 150 CT scans chest. CO-RADS was significantly co-related with neutrophils count at day 1 (r=0.93, \(p\)-value < 0.001), day 5 (r=0.47, \(p\)-value=0.001), day 14 (r=0.94, \(p\)-value<0.001), lymphocytes count at day 1 (r=0.15, \(p\)-value<0.001), day 5 (r=0.90, \(p\)-value<0.001), day 14 (r=0.83, \(p\)-value=0.004), CRP at day 1 (r=0.90, \(p\)-value=0.001), day 5 (r=0.36, \(p\)-value=0.011) and at day 14 (r=0.93, \(p\)-value=0.001).

**Conclusion:** The results of this study showed that the severity of lung involvement on high resolution CT (HRCT) chest positively correlate with laboratory parameters. The study provides an insight into the appropriate interval of chest CT to reduce radiation and promote timely management of COVID-19 patients.

**Key Words:** COVID-19, CO-RADS Score, High Resolution CT Chest, Laboratory Parameters.

**How to cite this:** Kashif S, Pervaiz E. Relationship between High Resolution CT Chest and Laboratory Parameters- An Assessment Tool for the Safe and Timely Management of Suspected/Confirmed Covid-19 Disease Patients. Life and Science. 2021; 2(2): 93-96. doi: http://doi.org/10.37185/LnS.1.1.145

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Introduction**
Coronavirus disease 2019 (COVID-19) is an infectious acute respiratory disease caused by a novel coronavirus. It has spread rapidly all over the world as compared to other deadly viruses of the same family (SARS-CoV and MERS-CoV).¹ Previous studies have shown clinical, laboratory, and radiologic characteristics of COVID-19.² Hsu LY et al showed raised alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in severe acute respiratory syndrome (SARS) patients.³ The radiological findings of coronavirus disease includes bilateral infiltrates with ground-glass opacities and in advance cases (COVID-19 pneumonia) consolidation.⁴ Pathological changes at cellular level showed diffuse alveolar damage.⁵ Yao XH et al found that the biopsy specimens of the liver showed mild lobular and portal activity and moderate microvascular steatosis, which suggest that the injury maybe induced by novel coronavirus.⁶ Heart
specimens showed no pathological changes, suggesting coronavirus infection may not damage the heart directly. In previous studies of critically ill patients with COVID-19, pathological changes in different organs, has been discussed but only little is known about association between lung changes and other organs involvement due to coronavirus. The aim of this study is to assess the importance of laboratory parameters and the relationship between lung changes on high resolution CT scan and blood markers of infection to avoid unnecessary exposure to radiation and timely management.

Materials and Methods
After ethical committee approval and informed consent, fifty COVID suspected patients (as per history) at COVID-19 isolation ward of Frontier Corps Hospital Quetta from April 15th to June 30th, 2020, were included. Patients on mechanical ventilation; septic shock; other organ failures, who required intensive care management, age > 65 years and patients with normal CT-chest patients were excluded from the study. Laboratory parameters including Neutrophils, Lymphocytes and C-reactive protein (CRP) were collected from medical records, retrospectively. Severity of lung changes on high resolution chest CT (CO-RADS) was scored according to the lung involvement (score 1-6). Spearman rank correlation was used to evaluate the relationship between CO-RADS score and laboratory parameters.

Statistical Analysis
All statistical analyses were performed by using SPSS statistical software (version 16). Categorical variables were described as frequency rates and percentages, and quantitative variables were described using mean± SD values. All chest CT scores were correlated with laboratory parameters at using the Spearman rank correlation. Difference between laboratory and radiographic data was obtained using one-way analysis of variance (ANOVA) with post hoc Tukey's multiple comparison tests at a level of significance $P<0.05$.

Results
A total of 50 patients (mean age 34.7±6.46 years) were evaluated. COVID-PCR negative cases were 14 (28.0%) and 36 (72.0%) were positive. Among males 13 (35.1%) were COVID-19 PCR negative and 24 (64.9%) were positive. Among females 1 (7.7%) was COVID PCR negative and 36 (72.0%) were found positive (Table 1). The patients underwent a total of 150 CT scans chest. CO-RADS was significantly co-related with neutrophils count at day 1 ($r=0.93$, $p$-value < 0.001), day 5 ($r=0.47$, $p$-value=0.001) , day 14 ($r=0.94$, $p$-value<0.001), lymphocytes count at day 1 ($r=0.15$, $p$-value<0.001), day 5 ($r=0.90$, $p$-value<0.001), day 14 ($r=0.83$, $p$-value=0.004), CRP at day 1 ($r=0.90$, $p$-value<0.001), day 5 ($r=0.36$, $p$-value=0.011) and at day 14 ($r=0.93$, $p$-value=0.001).

| Table 1: Demographic features |
|-------------------------------|
| PCR COVID-19                  |
| Negative                      |
| Male n (%) (35.1%)            |
| Female n (%) (7.7%)           |
| Total n (%) (28.0%)           |
| Positive                      |
| Male n (%) (64.9%)            |
| Female n (%) (92.3%)          |
| Total n (%) (72.0%)           |

| Table 2: Day-1 Lab parameters versus CT Scan Chest |
|---------------------------------------------------|
| CO-RADS at Day-1                                |
| Neutrophils at Day-1                            |
| Lymphocytes at Day-1                            |
| CRP at Day-1                                     |
| p-value                                          |
| Negative                                        |
| Mean± SD.DN                                     |
| 14±3.88                                         |
| 10±2.81                                         |
| 54.6±13.96                                      |
| 3.73±1.13                                       |
| Positive                                        |
| Mean± SD.DN                                     |
| 89.6±4.32                                       |
| 11.5±3.72                                       |
| 53.1±14.8                                      |
| 3.77±0.59                                       |
| Total                                           |
| Mean± SD.DN                                     |
| 89.1±4.23                                       |
| 11.3±3.52                                      |
| 53.6±14.8+13.54                                 |
| 3.77±0.77                                        |

| Table 3: Day-5 Lab parameters versus CT Scan Chest |
|---------------------------------------------------|
| CO-RADS at Day-5                                  |
| Neutrophils at Day-5                              |
| Lymphocytes at Day-5                              |
| CRP at Day-5                                      |
| p-value                                          |
| Negative                                        |
| Mean± SD.DN                                     |
| 73.14±6.68                                      |
| 17.00±3.92                                      |
| 50.00±12.2                                      |
| 2.85±0.53                                       |
| Positive                                        |
| Mean± SD.DN                                     |
| 74.94±7.15                                      |
| 15.91±4.87                                      |
| 43.05±13.6                                    |
| 3.02±0.65                                       |
| Total                                           |
| Mean± SD.DN                                     |
| 74.4±7.01                                       |
| 16.2±4.61                                      |
| 45.0±13.54                                    |
| 2.98±0.62                                        |

Discussion
The study showed that the degree of lung involvement on high resolution chest CT was correlated with blood markers of infection in COVID-19 patients. In previous studies, laboratory markers like D-Dimer, fibrinogen and C-reactive protein (CRP) between COVID-19 mild and severe cases, were significantly different. Fan et al. study on laboratory parameter of lymphocyte count and lactate dehydrogenase (LDH) level between COVID-19 intensive care unit (ICU) and non-ICU patients.
showed increased lactate dehydrogenase (LDH) and lymphopenia in ICU patients. Literature showed that MERS-CoV patients had deranged liver function with raised aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and LDH. Similarly, SARS patient showed raised CRP aminotransferase, creatine kinase and LDH along with lymphopenia and leukopenia. Recently published articles have also showed clinical and epidemiological characteristics of COVID-19 disease patients, but still patient’s data regarding laboratory characteristics are limited. High resolution chest CT a useful and effective tool to assess progress of disease according to the severity of COVID-19, and plays vital role in patient’s management. During acute infection, neutrophils act by phagocytosis and oxidative burst and, may contribute to organ damage and death, by forming extracellular traps. Neutrophil count was related to severity of disease according to literature. Infection-related biomarkers included white blood count, CRP, neutrophils and procalcitonin usually elevated due to progression of disease. Likewise, severe COVID on Chest CT showed diffuse ground glass opacities with consolidation. In critically ill COVID patients infection-related biomarkers, regulated by inflammatory cytokine, are grossly deranged.

Literature showed that neutrophil count is related to the severity of disease and neutrophil infiltration was also noted in pathological findings from autopsied COVID-19 patients. Other biomarkers like C-reactive protein and procalcitonin also gets elevated. Radiological findings showed diffuse alveolar damage with inflammatory cell infiltration in this stage. Accordingly, chest CT showed consolidation with ground glass opacities. Due to low immune functions, patients with severe viral infection are get co-infected with bacteria. Cytokine storm in severe and critically ill patients with COVID-19 might be associated with the activity of these infection-related biomarkers regulated by inflammatory cytokine. The decrease in lymphocytes in COVID-19 patients indicates that a large number of immune cells are consumed and the immune function is inhibited. The increase in neutrophil count, procalcitonin and C-reactive protein may be associated with cytokine storm due to viral invasion along with bacterial coinfection.

Timely prevention of infection may help reduce complication and mortality. Computed tomography plays an important role in the diagnosis and disease severity evaluation of this disease. There were some limitations of the study. Firstly, it was a retrospective study and the sample size was comparatively small. Therefore, more studies are required for the confirmation of investigatory findings.

Conclusion
The results of this study showed that the severity of lung involvement on high resolution CT (HRCT) chest positively correlate with laboratory parameters and this provides an insight into the appropriate interval of chest CT to reduce radiation and promote timely management of COVID-19 patients.

REFERENCES
1. Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery. 2020; 76: 71-6.
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507–13.
3. Hsu LY, Lee CC, Green JA, Ang B, Paton NI, Lee L, et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis. 2003; 9: 713–7.
4. Wang EA, Zenilman J, Brinkley-Rubinstein L. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 324: 1031-2.
5. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8; 420–2.
6. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Chinese journal of pathology. 2020; 49: E009.
7. Ortiz-Fernández L, Sawalha AH. Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations. Genes & Immunity. 2020; 21: 269-72.
8. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382: 727–33.
9. Zhang B, Zhang J, Chen H, Chen L, Chen Q, Li M, et al. Novel coronavirus disease 2019 (COVID-19): relationship between chest CT scores and laboratory parameters. European Journal of Nuclear Medicine and Molecular Imaging. 2020; 47: 2083-9.
10. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in
11. Fan BE, Chong VC, Chan SS, Lim GH, Lim KG, Tan GB, et al. Hematologic parameters in patients with COVID-19 infection. American journal of hematology. 2020; 95: E131-4.

12. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome(SARS) in Hong Kong. N Engl J Med. 2003; 348: 1986–94.

13. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, et al. Identification of severe acute respiratory syndrome (SARS) in Canada. N Engl J Med. 2003; 348: 1995–2005.

14. Mez J, Daneshvar DH, Kiernan PT, Abdolmohammadi B, Alvarez VE, Huber BR, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA. 2020; 318: 360-70.

15. Chung M, Adam B, Mei X, Zhang N, Huang M, Cui J, et al. CT Imaging Features of 2019 Novel coronavirus (2019-nCoV). Radiology. 2020; 295: 202–7.

16. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020; 2020; 295: 202–7.

17. Schönrich G, Raftery MJ. Neutrophil extracellular traps go viral. Front Immunol. 2016; 7: 366.

18. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S, et al. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res. 2020; 21: 74.

19. Shi H, Han X, Zheng C. Evolution of CT manifestations in a patient recovered from 2019 novel coronavirus (2019-nCoV) pneumonia in Wuhan, China. Radiology. 2020; 295: 20.

20. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020; 368:m606.

21. Fang Y, Zhang H, Xu Y, Xie J, Pang P, Ji W. CT manifestations of two cases of 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020; 295: 208-9.

22. Fang Y, Zhang H, Xu Y, Xie J, Pang P, Ji W. CT manifestations of two cases of 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020; 295: 208-9.

23. Feng P, Tianhe Y, Peng S, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID19) pneumonia. Radiology. 2020; 13: 200370.

24. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003; 361: 1319–25.

25. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348: 1977–85.

26. Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging coronavirus 2019-nCoV pneumonia. Radiology. 2020; 295: 210–7.

27. National Health and Health Commission and State Administration of traditional Chinese medicine. Diagnosis and treatment of pneumonia caused by new coronavirus infection (Trial version 5 [J/OL]). Chinese J Integrated Traditional Western Edicine. 2020; 40: 136-8.